TR200909787A2 - Pharmaceutical formulations containing a third generation cephalosporin and clavulanic acid. - Google Patents
Pharmaceutical formulations containing a third generation cephalosporin and clavulanic acid.Info
- Publication number
- TR200909787A2 TR200909787A2 TR2009/09787A TR200909787A TR200909787A2 TR 200909787 A2 TR200909787 A2 TR 200909787A2 TR 2009/09787 A TR2009/09787 A TR 2009/09787A TR 200909787 A TR200909787 A TR 200909787A TR 200909787 A2 TR200909787 A2 TR 200909787A2
- Authority
- TR
- Turkey
- Prior art keywords
- clavulanic acid
- generation cephalosporin
- pharmaceutical formulations
- formulations containing
- salts
- Prior art date
Links
- 229930186147 Cephalosporin Natural products 0.000 title abstract 2
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 title abstract 2
- 229940124587 cephalosporin Drugs 0.000 title abstract 2
- 150000001780 cephalosporins Chemical class 0.000 title abstract 2
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 title abstract 2
- 229960003324 clavulanic acid Drugs 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 abstract 3
- IPYWNMVPZOAFOQ-NABDTECSSA-N (6r,7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(carboxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;trihydrate Chemical compound O.O.O.S1C(N)=NC(C(=N\OCC(O)=O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 IPYWNMVPZOAFOQ-NABDTECSSA-N 0.000 abstract 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 241000894006 Bacteria Species 0.000 abstract 1
- 229960003719 cefdinir Drugs 0.000 abstract 1
- RTXOFQZKPXMALH-GHXIOONMSA-N cefdinir Chemical compound S1C(N)=NC(C(=N\O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 RTXOFQZKPXMALH-GHXIOONMSA-N 0.000 abstract 1
- 229960002129 cefixime Drugs 0.000 abstract 1
- LTINZAODLRIQIX-FBXRGJNPSA-N cefpodoxime proxetil Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC)C(=O)OC(C)OC(=O)OC(C)C)C(=O)C(=N/OC)\C1=CSC(N)=N1 LTINZAODLRIQIX-FBXRGJNPSA-N 0.000 abstract 1
- 229960004797 cefpodoxime proxetil Drugs 0.000 abstract 1
- 239000013078 crystal Substances 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cephalosporin Compounds (AREA)
Abstract
Bu buluş dirençli bakterilerin neden olduğu enfeksiyonların tedavisi için sefdinir, sefiksim ve sefpodoksim proksetil'i içeren grup içerisinden seçilen üçüncü kuşak bir sefalosporin ve klavulanik asit ve/ veya bunların farmasötik kabul edilebilir tuzları, hidratları, enantiomerleri, rasematları, organik tuzları, inorganik tuzları, esterleri, polimorflan, kristal formları ve amorf formları ve/veya bunlara ait kombinasyonları içeren farmasötik bileşimlere ilişkindir.The present invention is a third generation cephalosporin selected from the group consisting of cefdinir, cefixime and cefpodoxime proxetil for the treatment of infections caused by resistant bacteria and clavulanic acid and / or their pharmaceutically acceptable salts, hydrates, enantiomers, racemates, organic salts, inorganic salts, esters. relates to pharmaceutical compositions containing polymorphs, crystal forms and amorphous forms and / or combinations thereof.
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TR2009/09787A TR200909787A2 (en) | 2009-12-25 | 2009-12-25 | Pharmaceutical formulations containing a third generation cephalosporin and clavulanic acid. |
| EP10798856A EP2515905A1 (en) | 2009-12-25 | 2010-12-03 | Pharmaceutical formulations comprising a third generation cephalosporin and clavulanic acid |
| PCT/TR2010/000240 WO2011078820A1 (en) | 2009-12-25 | 2010-12-03 | Pharmaceutical formulations comprising a third generation cephalosporin and clavulanic acid |
| US13/532,120 US8614315B2 (en) | 2009-12-25 | 2012-06-25 | Cefdinir and cefixime formulations and uses thereof |
| US14/089,355 US20140079647A1 (en) | 2009-12-25 | 2013-11-25 | Cefdinir and cefixime formulations and uses thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TR2009/09787A TR200909787A2 (en) | 2009-12-25 | 2009-12-25 | Pharmaceutical formulations containing a third generation cephalosporin and clavulanic acid. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR200909787A2 true TR200909787A2 (en) | 2011-07-21 |
Family
ID=43568755
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2009/09787A TR200909787A2 (en) | 2009-12-25 | 2009-12-25 | Pharmaceutical formulations containing a third generation cephalosporin and clavulanic acid. |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP2515905A1 (en) |
| TR (1) | TR200909787A2 (en) |
| WO (1) | WO2011078820A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR201000686A1 (en) * | 2010-01-29 | 2011-08-22 | B�Lg�� Mahmut | Water-soluble cefdinir and clavulanic acid formulations for the treatment of bacterial infections. |
| TR201010212A2 (en) * | 2010-12-08 | 2012-06-21 | Bi̇lgi̇ç Mahmut | Solid oral dosage form containing cefdinir. |
| AU2017295866A1 (en) | 2016-07-14 | 2019-01-17 | Achaogen, Inc. | Combination of ceftibuten and clavulanic acid for use in the treatment of bacterial infections |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1508977A (en) | 1974-04-20 | 1978-04-26 | Beecham Group Ltd | Beta-lactam antibiotic from streptomyces clavuligerus |
| JO984B1 (en) | 1977-10-11 | 1979-12-01 | بيتشام غروب ليمتد | K-clavulanate/tri hydrate formulations |
| GB9408117D0 (en) | 1994-04-23 | 1994-06-15 | Smithkline Beecham Corp | Pharmaceutical formulations |
| ATE208618T1 (en) | 1995-09-07 | 2001-11-15 | Smithkline Beecham Corp | USE OF A PEDIATRIC PHARMACEUTICAL FORMULATION CONTAINING AMOXICILLIN AND CLAVULANATE |
| ES2202004T3 (en) | 1999-04-13 | 2004-04-01 | Beecham Pharmaceuticals (Pte) Limited | NEW PROCESSING PROCESSING USING A STRONG DOSAGE REGIME OF AMOXYCLINE AND POTASSIC CLAVULANATE. |
| FR2881755B1 (en) * | 2005-02-10 | 2012-11-30 | Biomerieux Sa | MEDIA FOR THE SPECIFIC DETECTION OF RESISTANT MICROORGANISMS |
| WO2007086012A1 (en) * | 2006-01-25 | 2007-08-02 | Jegannathan Srinivas | Formulation of cefpodoxime, clavulanic acid and linezolid |
| CN101129381B (en) * | 2006-08-25 | 2012-02-01 | 天津和美生物技术有限公司 | Combination of Antibiotics Containing β-Lactam Antibiotics and Ion Chelating Agents |
| CN101744827B (en) * | 2008-12-15 | 2012-05-30 | 天津中敖生物科技有限公司 | Pharmaceutical composition for treating chicken escherichia coli as well as preparation method and application thereof |
-
2009
- 2009-12-25 TR TR2009/09787A patent/TR200909787A2/en unknown
-
2010
- 2010-12-03 EP EP10798856A patent/EP2515905A1/en not_active Withdrawn
- 2010-12-03 WO PCT/TR2010/000240 patent/WO2011078820A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP2515905A1 (en) | 2012-10-31 |
| WO2011078820A1 (en) | 2011-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2012000125A1 (en) | Substituted carbamoylmethylamino acetic acid derivatives as novel nep inhibitors | |
| PH12014502224A1 (en) | Heterobicyclic compounds as beta-lactamase inhibitors | |
| MX2011007737A (en) | Hydroxy-methyl isoxazole derivatives as gaba a modulators. | |
| ECSP11010980A (en) | FUSIONED SPIROCYCLIC HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | |
| MX2011011484A (en) | Isoxazole-pyridine derivatives as gaba modulators. | |
| UY33731A (en) | ? AMINO-PHENYL-PENTANOIC ACID DERIVATIVES REPLACED AS NEP INHIBITORS? | |
| EA201391158A8 (en) | DIAMINIC PHENOTIAZINE SALTS AND THEIR APPLICATION | |
| PE20141204A1 (en) | NOVEL COMPOUNDS AS INHIBITORS OF DIACILGLICEROL ACILTRANSFERASE | |
| MX2011008501A (en) | Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors. | |
| WO2011093826A3 (en) | Effervescent formulations comprising cefaclor and clavulanic acid as active agents | |
| MX2011007772A (en) | Isoxazole / o-pyridine derivatives with ethyl and ethenyl linker. | |
| MX2013000295A (en) | Process of preparing a thrombin specific inhibitor. | |
| IN2012DN02502A (en) | ||
| PE20150021A1 (en) | 5-AMINO [1,4] THIAZINES AS BACE1 INHIBITORS | |
| MX2016002718A (en) | KETO-IMIDAZOPYRIDINE DERIVATIVES AS RORc MODULATORS. | |
| WO2010132670A3 (en) | Pentacycline compounds | |
| TR200909787A2 (en) | Pharmaceutical formulations containing a third generation cephalosporin and clavulanic acid. | |
| TR201005325A2 (en) | Pharmaceutical formulations containing atorvastatin and aspirin | |
| EA201101655A1 (en) | DERIVATIVES NITRILE, THEIR USE IN PHARMACEUTICAL PURPOSES AND IN COMPOSITIONS | |
| MX2012007870A (en) | Carboxylic acid derivatives having a 2,5,7-substituted oxazolopyrimidine ring. | |
| MX2012007836A (en) | Heterocyclic carboxylic acid derivatives having a 2,5-substituted oxazolopyrimidine ring. | |
| MX2012007834A (en) | Carboxylic acid derivatives having a 2,5-substituted oxazolopyrimidine ring. | |
| MX2012007833A (en) | Heterocyclic carboxylic acid derivatives having a 2,5,7-substituted oxazolopyrimidine ring. | |
| MX2013005966A (en) | Novel benzofurane compounds. | |
| WO2009131493A3 (en) | 5-hydroxy-4-aminomethyl-1-cyclohexane or (cycloheptyl)--3-alkoxycarbonyl indole derivatives, pharmaceutically acceptable antiviral salts thereof and a method for the production thereof |